+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy



Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy



Neuroendocrinology 94(4): 291-301



While incretins are of great interest for the therapy of diabetes 2, the focus has recently been brought to the thyroid, since rodents treated with glucagon-like peptide-1 (GLP-1) analogs were found to occasionally develop medullary thyroid carcinomas. Incretin receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) were therefore measured in various rodent and human thyroid conditions. In vitro GLP-1 and GIP receptor autoradiography were performed in normal thyroids, C-cell hyperplasia and medullary thyroid carcinomas in rodents. Receptor incidence and density were assessed and compared with the receptor expression in human thyroids, medullary thyroid carcinomas, and TT cells. GLP-1 receptors are expressed in C cells of normal rat and mice thyroids. Their density is markedly increased in rat C-cell hyperplasia and medullary thyroid carcinomas, where their incidence amounts to 100%. GIP receptors are neither detected in normal rodent thyroids nor in C-cell hyperplasia, but are present in all rat medullary thyroid carcinomas. No GLP-1 or GIP receptors are detected in normal human thyroids. Whereas only 27% of all human medullary thyroid carcinomas express GLP-1 receptors, up to 89% express GIP receptors in a high density. TT cells lack GLP-1 receptors but express GIP receptors. GLP-1 receptors are frequently expressed in non-neoplastic and neoplastic C cells in rodents while they are rarely detected in human C-cell neoplasia, suggesting species differences. Conversely, GIP receptors appear to be massively overexpressed in neoplastic C cells in both species. The presence of incretin receptors in thyroid C cell lesions suggests that this organ should be monitored before and during incretin-based therapy of diabetes.

(PDF emailed within 0-6 h: $19.90)

Accession: 053810384

Download citation: RISBibTeXText

PMID: 21893952

DOI: 10.1159/000330447


Related references

Inkretinforschung und Inkretin-basierte Diabetestherapie; Incretin research and incretin-based diabetes therapy;. Der Diabetologe 13(7): 474-474, 2017

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2013

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. Best Practice and Research. Clinical Endocrinology and Metabolism 23(4): 513-523, 2009

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

GLUT2 and the incretin receptors are involved in glucose-induced incretin secretion. Molecular and Cellular Endocrinology 276(1-2): 18-23, 2007

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes. Journal of Diabetes Investigation 3(1): 70-79, 2012

Incretin mimetics and incretin enhancers for the treatment of type 2 diabetes. Revue Medicale Suisse 3(122): 1884, 1886-8, 2007

Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes. Regulatory Peptides 122(3): 209-217, 2004

Treatment of generalized neopl hodgkins disease with multiple chemo therapy abstract from sem hop paris 42 49 2970 2974 nov 1966 human cortisone meta sulfo benzoate anti neoplastic orally procarbazine anti neoplastic natulan anti neoplastic vinblastine sulfate anti neoplastic vincaleukoblastine anti neoplastic tri ethylene melamine anti neoplastic triameline anti neoplastic tem anti neoplastic. Drug Digests 3(1): 45-46, 1967, 1968

β-cell function, incretin effect, and incretin hormones in obese youth along the span of glucose tolerance from normal to prediabetes to type 2 diabetes. Diabetes 63(11): 3846-3855, 2014

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Comparative Effects of Proximal and Distal Small Intestinal Glucose Exposure on Glycemia, Incretin Hormone Secretion, and the Incretin Effect in Health and Type 2 Diabetes. Diabetes Care 2019, 2019

Incretin-based therapy and type 2 diabetes. Vitamins and Hormones 84: 389-413, 2011